Although bnAbs can reduce viremia, delay viral rebound and prevent infection with sensitive viruses, clinical trials have highlighted limitations, such as HIV-1 Env diversity and pre-existing and de novo resistance1,13, impeding clinical applicability. Here, ERVW-1 is linked to infection.